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A B S T R A C T
Background
A randomized controlled trial (RCT) has shown that male circumcision (MC) reduces sexual
transmission of HIV from women to men by 60% (32%76%; 95% CI) offering an intervention of
proven efficacy for reducing the sexual spread of HIV. We explore the implications of this
finding for the promotion of MC as a public health intervention to control HIV in sub-Saharan
Africa.
Methods and Findings
Using dynamical simulation models we consider the impact of MC on the relative prevalence
of HIV in men and women and in circumcised and uncircumcised men. Using country level data
on HIV prevalence and MC, we estimate the impact of increasing MC coverage on HIV
incidence, HIV prevalence, and HIV-related deaths over the next ten, twenty, and thirty years in
sub-Saharan Africa. Assuming that full coverage of MC is achieved over the next ten years, we
consider three scenarios in which the reduction in transmission is given by the best estimate
and the upper and lower 95% confidence limits of the reduction in transmission observed in
the RCT.
MC could avert 2.0 (1.13.8) million new HIV infections and 0.3 (0.10.5) million deaths over
the next ten years in sub-Saharan Africa. In the ten years after that, it could avert a further 3.7
(1.97.5) million new HIV infections and 2.7 (1.55.3) million deaths, with about one quarter of
all the incident cases prevented and the deaths averted occurring in South Africa. We show that
a) MC will increase the proportion of infected people who are women from about 52% to 58%;
b) where there is homogenous mixing but not all men are circumcised, the prevalence of
infection in circumcised men is likely to be about 80% of that in uncircumcised men; c) MC is
equivalent to an intervention, such as a vaccine or increased condom use, that reduces
transmission in both directions by 37%.
Conclusions
This analysis is based on the result of just one RCT, but if the results of that trial are confirmed
we suggest that MC could substantially reduce the burden of HIV in Africa, especially in
southern Africa where the prevalence of MC is low and the prevalence of HIV is high. While the
protective benefit to HIV-negative men will be immediate, the full impact of MC on HIV-related
illness and death will only be apparent in ten to twenty years.
The Editors’ Summary of this article follows the references.
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Introduction
Ambitious targets have been set for the control of the HIV
pandemic [1–3]. While access to life-saving anti-retroviral
therapy (ART) for those infected with HIV is increasing
rapidly throughout the world, effective programmes to reduce
HIV transmission are still needed [4], especially in Africa.
Many factors inﬂuence the risk of acquiring and transmitting
HIV [5], but where measures intended to reduce transmission
have been rigorously tested at a population level, the results
have been mixed [6,7]. Furthermore, an effective vaccine will
probably not be available for a decade or more [8].
There is now clear evidence that male circumcision (MC)
signiﬁcantly reduces female-to-male transmission of HIV. In
the ﬁrst randomized controlled trial (RCT) to report on MC,
Auvert and colleagues [9] have shown that MC reduces
transmission from women to men by 60% (32%76%; unless
otherwise stated ranges are 95% CI). An earlier meta-analysis
of observational studies found an adjusted relative risk for
HIV in circumcised men of 0.42 (0.340.54) [10], although a
Cochrane review gave a more cautious interpretation [11]. In
sub-Saharan Africa, estimates of HIV prevalence [12] (Figure
1) are signiﬁcantly associated with the estimated prevalence
of MC (correlation coefﬁcient, q ¼ 0.61; p , 0.0001). In
countries where fewer than 30% of men are circumcised, the
median prevalence of HIV is 17% (IQR: 6% to 27%, n ¼ 9
countries); where more than 90% of men are circumcised it is
2.9% (IQR: 1.5% to 5.5%, n¼ 13 countries). In a multi-centre
study in Africa, Herpes simplex 2 and not being circumcised
were independent risk factors for HIV [13]; the prevalence of
HIV was negatively correlated with the proportion of men
who were circumcised (correlation co-efﬁcient, q¼0.85; p ,
0.001) [14]. RCTs in Kenya [15] and Uganda [16] will provide
further information on the impact of MC on HIV and in
particular on the possible impact of MC on male-to-female
transmission of HIV.
The impact of increasing MC coverage on HIV depends on
the prevalence of HIV and of MC and we assess this impact
using both static and dynamic models. For purposes of
illustration, country estimates are aggregated to four regions,
but we also present results for South Africa where MC could
have the greatest impact and where the estimates of MC and
HIV prevalence are reliable. Estimates are made of the
reduction in incidence, prevalence, and deaths in each region.
Assuming that the prevalence of MC is increased from present
levels to full coverage (as deﬁned in Protocol S1 and illustrated
in Figure S1) in either 2010 or 2015, we determine the relative
impact that MC will have on HIV incidence, prevalence, and
related mortality among circumcised and uncircumcised men
and on women over the next thirty years. We consider MC
independently of the changes that might arise from the
implementation of other effective prevention programmes in
order to focus on the impact of increasing MC coverage.
Methods
To estimate the potential impact of MC on HIV prevalence,
we ﬁrst use a static model to estimate DJ, the reduction in the
incidence of infection J. Using the result derived below
(Equations 8–10), the reduction in incidence, if all men were
circumcised, would be
D J ¼ 1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 p
1 pv
s !
J ð1Þ
where p is the reduction in HIV transmission from women to
men, v is the proportion of men who are already circumcised,
and the incidence is taken to be one-tenth of the current
prevalence, corresponding to a mean life expectancy of ten
years in the endemic state.
The reduction in incidence, calculated using Equation 1,
gives an estimate of the impact of MC on the incidence of
HIV but does not account for changes in the long-term
dynamics of the epidemic. An immediate reduction in the
rate of new infections will only be reﬂected in the prevalence
of HIV and HIV-related deaths some years later, because
prevalence depends on cumulative incidence and the mean
time from infection to death is about ten years. For this
reason, we also develop dynamic models to explore the
impact of MC on incidence, prevalence, and deaths over
several decades.
Although the models are general, we focus the discussion of
the model development on parameter values pertaining to
South Africa, which has the best national data on HIV and
where MC is likely to have the biggest impact. We extrapolate
to other countries by adjusting the relevant parameters to ﬁt
the data on national trends in HIV prevalence and the local
prevalence of MC.
Parameter Estimates for South Africa
Early in the epidemic, the prevalence of HIV in South
Africa increased exponentially at a rate r ¼ 0.55 6 0.16/year,
giving an intrinsic doubling time d ¼ 1.26 6 0.37 years [17].
Figure 1. The Relationship between the Prevalence of HIV and MC in
Sub-Saharan Africa
The percent prevalence of HIV [12] is plotted on a logarithmic scale
against the estimated proportion of adult men who are circumcised
[32,33].
Green, southern Africa; red, East Africa; orange, Central Africa; blue, West
Africa.
C, Central Africa; E, East Africa; S, South Africa; W, West Africa.
ANG, Angola; BEN, Benin; BOT, Botswana; BUF, Burkina Faso; BUR,
Burundi; CAM, Cameroon; CAR, Central African Republic; CHA, Chad;
CON, The Congo; DJI, Djibouti; DRC, Democratic Republic of the Congo;
EQA, Equatorial Guinea; ERI, Eritrea; ETH, Ethiopia; GAB, Gabon; GAM,
Gambia; GHA, Ghana; GUB, Guinea Bissau; GUI, Guinea; IVO, Coˆte d’Ivoire;
KEN, Kenya; LES, Lesotho; LIB, Liberia; MAL, Mali; MAU, Mauritania; MAW,
Malawi; MOZ, Mozambique; NAM, Namibia; NIA, Nigeria; NIR, Niger; RWA,
Rwanda; SEN, Senegal; SIE, Sierra Leone; SOA, South Africa; SOM,
Somalia; SUD, Sudan; SWA, Swaziland; TAN, Tanzania; TOG, Togo; UGA,
Uganda; ZAM, Zambia; ZIM, Zimbabwe.
DOI: 10.1371/journal.pmed.0030262.g001
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The life expectancy after infection with HIV and without
ART, standardized to a mean age at infection of 27 years, is s
¼ 9.8 6 0.5 years [18,19]. The average mortality rate d¼ 1/s is
then 0.102 6 0.005/year and the case reproduction number
R0 ¼ (r þ d)/d is 6.4 6 1.6 [20], where we have used Monte
Carlo sampling from normal distributions to estimate the
standard deviations [21].
Asymmetry in Sexual Transmission
An infected man is about twice as likely, per contact, to
infect a susceptible female partner, as an infected woman is
to infect a susceptible male partner. In two European studies,
the transmission ratio was 2.3 (1.14.8) [22] and 1.9 (1.13.3)
[23], respectively, although the ratio was signiﬁcantly lower
for sex during menses and higher for anal sex and for sex
involving older women [22]. The results of the RCT [9] suggest
that MC will increase the transmission ratio by a further
factor of 2.5 (1.54.2).
Relative Prevalence of HIV in Men and in Women
To determine the relative prevalence of HIV in men and
women as a function of the transmission parameters, we use a
two-sex, susceptible–infected model. We let if and im be the
prevalence of HIV in women and men. We assume that HIV-
related mortality, d, is independent of time since infection to
facilitate the development of analytical expressions that can be
used to parameterize the different effects on men and women
in terms of an overall effect averaged over men and women. In
the detailed analysis below (Equations 12–15), we represent
HIV-related mortality using a Weibull survival curve [24].
Although viral load is high during primary infection and
near the end of life, we assume here that infectiousness is
independent of time since infection. Then assuming an
effective contact rate c, and probabilities of infection per
contact of /m for female-to-male transmission and /f for
male-to-female transmission, the model is
dif
dt
¼ /f cimð1 if Þ  dif ð2Þ
dim
dt
¼ /mcif ð1 imÞ  dim ð3Þ
Early in the epidemic, if and im are both much less than 1, the
initial growth rate is
r ¼ c
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
/m/f
q
 d; ð4Þ
the ratio of the prevalence in women to that in men in the
early stages of the epidemic is
if
im
¼
ﬃﬃﬃﬃﬃﬃ
/f
/m
s
; ð5Þ
while the case reproduction number is
R0 ¼
c
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
/f/m
q
d
: ð6Þ
In the endemic state, the ratio of the prevalence in women to
that in men is
if
im
¼ 1þ d=c/m
1þ d=c/f
: ð7Þ
For the South African epidemic, if no men were circumcised,
we estimate that R0¼ 7.2 6 1.8 so that with d¼ 0.102 6 0.005/
y and /f / m ¼ 2.0 6 0.5 Equation 6 gives c/m ¼ 0.52 6 0.16/
year and c/f¼ 1.04 6 0.29/y. From Equation 7 the proportion
of infected adults who are women is 52% 6 1%. (A more
detailed examination of the proportion of infected adults
who are women is given in Protocol S1 and Figure S2.)
Collapsing the Two-Sex Model to a One-Group Model
To determine rates of infection, averaged over men and
women, we replace Equations 2 and 3 by
di
dt
¼ kið1 iÞ  di ð8Þ
where i is the population prevalence averaged over men and
women, and k ¼ c ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ/m/f
s
so that R0 for Equation 8 is the same
as in Equation 6. It follows that reducing /m by a factor of 1
p is equivalent to reducing both /m and /f by a factor ofﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 pp .
To allow for the fact that not all men are circumcised, we
let v be the proportion of men who are circumcised and p be
the reduction in female-to-male infectiousness when men are
circumcised. Then assuming random mixing the average
female-to-male infectiousness is reduced to
/mðvÞ ¼ vð1 pÞ/mð0Þ þ ð1 vÞ/mð0Þ ¼ ð1 vpÞ/mð0Þ: ð9Þ
If the proportion of men who are already circumcised is v,
the effect of circumcising all men will be to reduce /m to
/mð1Þ ¼
1 p
1 vp/mðvÞ: ð10Þ
In Protocol S1 and Figures S4 and S5, we analyse a three-
group model (distinguishing women, circumcised men, and
uncircumcised men), and show that under certain assump-
tions it can be reduced to a one-group model with errors of
less than 2.5% in the endemic prevalence for parameter
values of interest.
The Effect of Heterogeneity in Sexual Activity
Levels of sexual activity are highly skewed [25,26]. If men
and women have contact rate distributions with means cm and
cf , and variances r2m and r
2
f , and mixing is random, then
Equation 6 still holds [27] but with
c ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
cm þ r
2
m
cm
 
cf þ
r2f
cf
 !vuut ð11Þ
so that heterogeneity in sexual activity increases R0. However,
MC only affects the transmission probabilities /m and /f and
not the contact rates cm and cf, so that Equations 6–10 still
hold.
With R0’ 6, the predicted steady state prevalence, (R01)/
R0 ’ 83%, is much higher than is generally observed. In some
models this is allowed for by assuming that people have either
zero risk or a ﬁxed risk, and then varying the risk-free
fraction to ﬁt the steady-state prevalence [28]. If we assume,
more realistically, that there is a continuous distribution of
risk, those at greater risk will tend to be infected earlier, and
the risk of infection for uninfected people will fall as
prevalence rises. Here we assume (and corroborate with
South African data) that the average contact rate for those
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e2621034
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who are uninfected declines exponentially with prevalence
(see Protocol S1 and Figure S6).
The Aggregate Model
Based on the above arguments, we constructed an
aggregate model in which we considered the HIV prevalence,
incidence, and related deaths averaged over circumcised and
uncircumcised men. The model was ﬁtted to the available
time series of HIV prevalence for each country and used to
make projections. We let S(t) and I(t) be the number of
susceptible and infected adults over the age of 15 years at
time t, with N(t)¼ S(t)þ I(t), and i(t)¼ I(t)/N(t). Adults enter the
population at risk at a rate b times the population 15 years
earlier so that the total population growth rate matches the
reported values for each country [29]. To allow for hetero-
geneity in sexual behaviour and to ﬁt the observed asymptotic
prevalence of infection, the transmission parameter takes the
value k0 at the start of the epidemic and declines exponen-
tially at rate a times the prevalence of infection. The
background death rate is l. We use a Weibull survivorship,
W(t), with a median of 9.8 years and a shape parameter of 2.25
to capture the dependence of HIV-related mortality on time
since infection [24]. The model is then
dS
dt
¼ bNðt 25Þ  k0eaI=NSI=N  lS ð12Þ
dI
dt
¼ k0eaI=NSI=N  lI  D ð13Þ
D ¼ ðk0eaI=NSI=NÞ W ð14Þ
where  indicates convolution (see Protocol S1) and D is
number of HIV-related deaths per unit time. For those few
countries, such as Uganda, where there is evidence that the
prevalence of HIV is falling, we allow the transmission
parameter to decline with mortality, D/N, to account for
behavioural changes in response to the epidemic. To do this,
we multiply k0 in Equations 12–14 by e
eD/N and vary e to ﬁt
the data.
The dynamic model was ﬁtted to the UNAIDS estimates of
national HIV prevalence in adults by least-squares. Epidemics
were projected 30 years into the future assuming that the
coverage of MC increases logistically (see Protocol S1 and
Figure S1) from present levels to full coverage over ten years.
Changing MC coverage is allowed for by scaling k0 as in
Equations 9 and 10. Three scenarios were considered for the
impact of MC on female-to-male transmission of HIV
corresponding to the best estimate and to the lower and
upper 95% conﬁdence limits from the RCT [9].
Data
The data on circumcision (Table 1) are taken from a study
by Murdock in 1967 [30] updated by Bongaarts et al. in 1989
[31] and adjusted for ethnic groups by Wendell and Werker in
2004 [32]. We updated these estimates further using data
from Demographic and Health Surveys (DHS) carried out by
Macro International (Calverton, Maryland, United States) in
Kenya, Tanzania, Mozambique, Uganda, Burkina Faso, Ca-
meroon, and Ghana [33], and on national population–based
surveys carried out in Botswana [34] and South Africa [35]. A
study in Tanzania [36] where 41% of men were circumcised,
found that self-reported MC had a sensitivity of 94% and a
speciﬁcity of 72%, so self-reported rates may overestimate
true rates. The most important change to the earlier data
arises from the assumption that men in a particular ethnic
group, bordering Ghana and Coˆte d’Ivoire, are not circum-
cised. The DHS survey for Ghana suggests that 95% of men
are circumcised in contrast to the earlier estimate of 42%
[32]. A study carried out in Abidjan [37] suggests that in Coˆte
d’Ivoire the true rate of circumcision is 93%. We used these
values here. The estimates of HIV prevalence are from
UNAIDS [12], the estimates of population size and growth
rates are from the United Nations Development Programme
[29]. Data for the time trend in the prevalence of HIV in
South Africa were obtained from the series of 14 annual
antenatal clinic surveys [38].
Results
In West Africa MC is common and the prevalence of HIV is
low (Figure 1 and Figure 2A and 2B), while in southern Africa
the reverse is true. Using these values in our static model
(Equation 1), circumcising all uncircumcised men in Africa
would reduce the incidence of HIV as shown in Figures 2C
and 2D. When incidence is measured as an absolute reduction
in the number of incident infections expressed as proportion
of the adult population, the potential reduction in HIV
transmission is greatest in southern Africa (Figure 2); when
measured as a reduction in the total number of incident
cases, the region of greatest impact extends to parts of East
and Central Africa, as well as Ethiopia and Nigeria, which
have large populations (Figure 2). In South Africa alone,
increasing MC coverage has the potential to avert up to
174,000 new infections each year (Table 1).
While useful and immediate, the results in Figure 2 do not
provide estimates of the differential impact of MC on the risk
of infection in circumcised and uncircumcised men and in
women, and do not capture the temporal dynamics of the
impact on incidence, prevalence, and deaths. Using a two-sex
model (Equation 7), we ﬁrst determine the ratio of the
prevalence of HIV in women to men at the steady state. In
South Africa, if no men were circumcised, we predict that
52% 6 4% of HIV-positive adults would be women, whereas
if all men were circumcised this proportion would increase to
58% 6 4%. Using a three-group model (Protocol S1), the
expected prevalence of HIV in circumcised men is close to
80% of that in uncircumcised men regardless of the overall
proportion of men who are circumcised (see Figure S3). We
note that these results assume random mixing and use a
simpliﬁed description of heterogeneity in risk behaviour;
where this assumption is not true the relative prevalence in
the two groups of men may be different. Whereas MC
provides greater long-term beneﬁts to circumcised than to
uncircumcised men, and to men than to women, the differ-
ences in the steady-state prevalence among the three groups
are not large and suggest that the use of a simpliﬁed one-
group model will be acceptable.
In developing a one-group model to ﬁt country-level data
and to project changes in HIV incidence, prevalence, and
deaths, we note (Equation 6) that reducing female-to-male
transmission by a proportion p, without changing male-to-
female transmission, is equivalent to reducing transmission in
the one-group model by factor of 1 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ1 pp . In particular, if
MC reduces female-to-male transmission by 60%, then this is
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equivalent to reducing transmission in the one-group model
by 37%, so that MC would have a population-level impact
equivalent to an intervention that reduces transmission in
both directions by 37%.
We ﬁtted this model to UNAIDS estimates of HIV
prevalence over time for each country in sub-Saharan Africa
to determine the model parameters, as illustrated for South
Africa in Figure 3. The centre panel (Figure 3B) shows the
prevalence of HIV in South Africa obtained from national
antenatal clinic data [38], adjusted to match UNAIDS
estimates for the adult population [12]. We ﬁt the model to
the prevalence data, from which incidence (Figure 3A) and
deaths (Figure 3C) follow directly. We then allow MC
coverage to increase from 35% in 2005 to full coverage in
2015 and in 2010 (see Protocol S1) as illustrated in the top
three panels and bottom three panels of Figure 3, respec-
tively.
We ﬁrst examine the impact on HIV if full coverage of MC
is reached in 2015. The incidence of HIV infection responds
immediately to the intervention (Figure 3A) and by 2015 is
close to its new asymptotic value. Prevalence responds more
slowly and only approaches its new asymptotic value in 2025,
while the reduction in mortality is slower still. In South Africa
(Figure 3 and Table 2), MC could avert 0.5 (0.31.0) million
infections but only 0.1 (0.00.1) million deaths in the ﬁrst
decade of the program, 0.9 (0.51.8) million new infections
and 0.7 (0.41.3) million deaths in the following decade, and
1.0 (0.52.0) million new infections and 1.2 (0.62.3) million
deaths in the decade after that. The percentage reductions
from the baseline scenario (with no increase in MC) as shown
Table 1. The Potential Reduction in HIV Incidence for Countries in Sub-Saharan Africa
Country and
Country Code
Region (Central,
East, Southern
or West)
Population Aged
15–49 Years
(Millions)
Population Growth
Rate
(Percent/Year)
Prevalence
of MC
(Percent)
Adult Prevalence
of HIV
(Percent)
Reduction in
Incidence
(Percent/Year)
Reduction in
Incidence
(Thousands/Year)
Angola C 6.28 2.8 66 3.9 0.07 4.56
Central African
Republic
C 1.81 1.3 67 13.5 0.25 4.45
Chad C 3.98 3.4 64 4.8 0.09 3.71
The Congo C 1.72 3.0 70 4.9 0.08 1.43
Dem. Rep. Congo C 24.96 2.8 70 4.2 0.07 17.77
Gabon C 0.67 1.7 93 8.1 0.04 0.26
Burundi E 3.41 3.0 2 6.0 0.22 7.43
Djibouti E 0.34 2.1 94 2.9 0.01 0.04
Eritrea E 2.09 4.3 95 2.7 0.01 0.20
Ethiopia E 33.55 2.4 76 4.4 0.06 21.04
Kenya E 16.70 2.2 84 6.7 0.07 11.41
Rwanda E 3.98 2.4 10 5.1 0.18 7.06
Somalia E 4.69 3.2 93 0.7 0.00 0.16
Sudan E 17.27 1.9 47 2.3 0.06 10.07
Tanzania E 18.09 2.0 70 8.8 0.15 26.99
Uganda E 11.64 3.4 25 4.1 0.13 14.98
Botswana S 0.91 0.1 25 37.3 1.17 10.66
Lesotho S 0.86 0.1 0 28.9 1.06 9.15
Malawi S 5.45 2.3 17 14.2 0.47 25.74
Mozambique S 9.02 2.0 56 12.2 0.27 24.63
Namibia S 0.94 1.4 15 21.3 0.72 6.78
South Africa S 24.47 0.8 35 24.6 0.71 173.61
Swaziland S 0.51 0.2 50 38.8 0.95 4.80
Zambia S 4.89 1.7 12 16.5 0.57 27.70
Zimbabwe S 6.26 0.6 10 24.6 0.86 53.56
Benin W 3.31 3.2 84 1.9 0.02 0.64
Burkina Faso W 6.06 3.2 89 4.2 0.03 1.87
Cameroon W 7.89 1.9 93 6.9 0.03 2.65
Equatorial Guinea W 0.00 2.3 86 12.0 0.11 0.00
Gambia W 0.72 2.8 90 1.2 0.01 0.06
Ghana W 10.99 2.1 95 3.1 0.01 1.21
Guinea W 4.09 2.2 83 3.2 0.03 1.40
Guinea Bissau W 0.68 3.0 91 4.0 0.02 0.17
Coˆte d’Ivoire W 8.38 1.6 93 7.0 0.03 2.86
Liberia W 1.62 1.4 70 5.9 0.10 1.62
Mali W 5.98 3.0 95 1.9 0.01 0.40
Mauritania W 1.43 3.0 78 0.6 0.01 0.11
Niger W 5.50 3.4 92 1.2 0.01 0.36
Nigeria W 60.24 2.2 81 5.4 0.06 38.33
Senegal W 5.13 2.4 89 0.8 0.01 0.30
Sierra Leone W 2.44 4.1 90 1.8 0.01 0.30
Togo W 2.40 2.7 93 4.1 0.02 0.48
Table 1 gives countries and regions, the adult population size and growth rate [29], the prevalence of MC [30–35] and HIV in 2003 [12], and the potential reduction in the incidence
expressed as an absolute percentage per year and then as the number of incident cases per year, using Equation 1.
DOI: 10.1371/journal.pmed.0030262.t001
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in Table 2 are much less in West Africa than in the other
regions, but, because of the large population, the number of
cases or deaths averted in West Africa is almost as great as in
Central Africa, although still much less than in East and
southern Africa. Over the 20 years from 2005 to 2025, in the
whole of sub-Saharan Africa, MC could avert 5.7 million new
cases and 3.0 million deaths, while reducing the number of
people infected with HIV in 2025 by 4.1 million (Table 2). We
note that in South Africa the prevalence of HIV is high and
the prevalence of MC is low, but the population is large, and
approximately one-quarter of all infections prevented and
deaths averted could be in South Africa.
Figure 3D–3F repeats Figure 3A–3C, but with the inter-
vention being introduced twice as quickly and reaching full
coverage in 2010. While the incidence declines much more
rapidly (Figure 3D and 3A, respectively), there is little change
in the rate at which prevalence and deaths respond (Figure 3E
and 3B; Figure 3F and 3C; respectively), reﬂecting the low
incidence and slow progression to death for people infected
with HIV.
Discussion
Our analysis uses a simple, parsimonious model to evaluate
the potential impact of MC, and further empirical research is
needed to support more detailed models. However, this
analysis shows that MC could avert nearly six million new
infections and save three million lives in sub-Saharan Africa
over the next twenty years. Especially in southern Africa this
could go some way to meeting the 2001 United Nations
General Assembly Special Session on AIDS targets, the
Millennium Development Goals, and the objectives set by
bilateral donors, such as the US President’s Emergency Plan
for AIDS Relief.
Many questions remain to be answered. Better data are
needed on the national prevalence of HIV in Africa, as well as
on the associated uncertainties. UNAIDS gives plausibility
bounds for estimates of national HIV prevalence that are
typically about 630% [12], so the absolute values of the
estimates presented here are also uncertain to this extent,
although the trends should be more reliable. Better data are
also needed on the prevalence of MC in Africa and on the age
at circumcision, preferably at the subnational level. Most of
the currently available data on the prevalence of MC are
several decades old, while several of the recent studies were
carried out as adjuncts to demographic and health surveys
and were not designed to determine the prevalence of MC
[33]. Without such data it is difﬁcult to make reliable
estimates of the overall uncertainty in the potential impact
of MC on HIV in Africa. Data are also needed on current
circumcision practices, especially with regard to safety, on the
acceptability of MC, on the cost of MC, and on the feasibility
of making it available in places where it is not routinely done.
A detailed study is needed of the cost effectiveness of MC as a
way of managing the HIV epidemic in Africa using a dynamic
model of transmission, accounting for the cost of MC and
allowing for the savings that follow reductions in AIDS-
related morbidity and the need for ART. In addition, this
analysis is based on the result of just one RCT; it will be
necessary for the results of that trial to be conﬁrmed before it
is clear how accurate these estimates of future infections are.
While the models presented here are a ﬁrst step towards
Figure 2. The Geographical Distribution of MC, HIV Prevalence, and the
Potential Reduction in HIV Incidence if All Men Were Circumcised
(A) Proportion of men who are circumcised, v (%).
(B) Prevalence of HIV in 2003, P (%).
(C) Potential impact of MC on the incidence of HIV infection, DJ (% per
year), calculated using Equation 1.
(D) Potential reduction in the number of new adult infections each year
DJN, where N is the adult population (thousands per year).
The incidence, J, is taken to be one-tenth of the prevalence, P. The data
on which these maps are based are given in Table 1.
Disclaimer: The designations used and the presentation of material in
Figure 2 do not imply the expression of any opinion whatsoever on the part
of the World Health Organization concerning the legal status of any
country, territory, city, or area, or of its authorities, or concerning the
delimitation of its frontiers or boundaries.
DOI: 10.1371/journal.pmed.0030262.g002
Figure 3. Time Trends in the HIV Incidence, Prevalence, and Related
Mortality in South Africa if the Proportion of Circumcised Men Remains
Constant or Is Increased to Full Coverage (over Five or Ten Years)
(A) HIV incidence
(B) HIV prevalence
(C) HIV-related mortality in South African adults assuming that full
coverage of MC is reached in 2015. The model is fitted to the blue data
points in (B).
(D–F) Repeat (A–C) but assuming that full coverage is reached in 2010
(see Protocol S1).
The blue lines give the projected values excluding the impact of MC or
other additional interventions. The red, green, and pink lines give the
projected values assuming that MC reduces female-to-male transmission
by 32%, 60%, and 76%, respectively, corresponding to the estimated
reduction and 95% confidence intervals observed in the RCT of MC [9].
On all graphs, the blue boxes on the left mark the period 2005 to 2015,
the blue boxes on the right mark the period 2015 to 2025.
DOI: 10.1371/journal.pmed.0030262.g003
PLoS Medicine | www.plosmedicine.org July 2006 | Volume 3 | Issue 7 | e2621037
Male Circumcision and HIV in Africa
predicting the impact of MC on HIV in Africa, more detailed
models are needed to explore the effect of MC on the age-
speciﬁc incidence and prevalence of HIV among men and
women and on the relative beneﬁts of initially targeting men
in certain age groups or in high risk occupations, such as
truck drivers or mine workers.
Synergies with other potential interventions, including
HIV vaccines, should also be explored, as well as possible
synergies acting through the impact of MC on other sexually
transmitted infections. Since R0 for HIV is on the order of 5–
10, the 37% reduction in overall transmission associated with
MC could make a signiﬁcant contribution towards reaching
the target of reducing R0 to 1 in the areas where few men are
currently circumcised. Combined with other interventions to
reduce transmission, this raises the possibility of reducing the
prevalence of HIV to such low levels that it is no longer a
major public health problem. The impact of MC in South
Africa may also be mediated by its impact on other sexually
transmitted infections; the results of the other two RCTs of
MC, currently being conducted in Kenya [15] and Uganda [16]
where the prevalence of other sexually transmitted infections
may be different, should throw light on this.
The impact of MC on HIV should also be considered in the
context of the increasing availability of ART. To the extent
that ART reduces transmission, it will also reduce R0 and act
synergistically with MC. Many studies have shown that ART
leads to substantial declines in plasma viral load [39] and may
reduce the risk of transmission for those on ART [40].
However, if people in Africa start ART late in the course of
their HIV infection, the provision of ART is unlikely to
reduce overall transmission signiﬁcantly [41,42].
As a cautionary note, increases in risk-taking behaviour
among circumcised men could reduce the beneﬁt of MC. The
RCT [9] on which these models are based followed men for an
average of 18 months, so that the effects of short-term
behaviour changes have been accounted for. Community or
population level studies of MC are now needed to determine
the likelihood of behavioural disinhibition and to assess its
impact on transmission in the long term.
While MC confers greater direct beneﬁts on men than on
women, women beneﬁt indirectly through the reduction in
the prevalence of HIV among their male sexual partners.
Nevertheless, it is already the case that in Africa more women
than men are infected with HIV [12], and additional methods
that help to protect women, such as the development of
effective vaginal microbicides, are still needed. A trial under
way in Uganda [16] has been designed to measure the impact
of MC on male-to-female transmission of HIV.
The earlier observational studies and the recent RCT all
suggest that MC will have a long-term, population-level
impact on HIV transmission. However, this assumption needs
to be tested at the population level, and a large-scale,
community-based programme to implement MC as widely
as possible should be implemented and carefully monitored
to determine the population level impact of MC directly.
This analysis makes it clear that MC could have an
immediate impact on HIV transmission, but the full impact
on prevalence and deaths will only be apparent about ten to
ﬁfteen years later. The reason is that circumcision averts
infections some years into the future among people who
would have died ten years later, on average. The same
argument applies, of course, to other prevention methods
because reductions in illness and death will only be
manifested a decade or more after their introduction. The
need to keep HIV-positive people alive through the provision
of ART remains the most immediate priority while ways are
found to reduce transmission using MC and other inter-
ventions.
Table 2. Impact of MC on HIV Incidence, Prevalence, and Related Deaths in Africa
Region Time Period Incident Cases
Averted
(Millions)
Reduction in
Incident Cases
(Percent)
Prevalent Cases
Averted
(Millions)
Reduction in
Prevalent Cases
(Percent)
Deaths Averted
(Millions)
Reduction in
Mortality
(Percent)
Sub-Saharan 20052015 2.0 (1.13.8) 8 (417) 2.2 (1.24.3) 8 (417) 0.3 (0.10.5) 1 (12)
20152025 3.7 (1.97.5) 14 (632) 4.1 (2.08.3) 13 (631) 2.7 (1.55.3) 9 (519)
20252035 4.4 (2.29.0) 13 (632) 4.7 (2.49.7) 13 (630) 4.9 (2.59.9) 14 (734)
Central 20052015 0.2 (0.10.3) 8 (417) 0.2 (0.10.4) 8 (417) 0.0 (0.00.0) 1 (02)
20152025 0.4 (0.20.8) 15 (736) 0.4 (0.20.9) 15 (737) 0.2 (0.10.5) 9 (420)
20252035 0.5 (0.31.1) 16 (739) 0.6 (0.31.2) 15 (739) 0.5 (0.31.1) 16 (739)
East 20052015 0.5 (0.31.0) 9 (418) 0.6 (0.31.2) 9 (418) 0.1 (0.00.1) 1 (12)
20152025 1.0 (0.52.0) 14 (733) 1.1 (0.62.3) 14 (734) 0.8 (0.41.5) 10 (520)
20252035 1.3 (0.62.6) 14 (735) 1.4 (0.72.9) 14 (634) 1.4 (0.72.8) 15 (736)
Southern 20052015 1.0 (0.61.9) 11 (622) 1.2 (0.72.1) 11 (623) 0.1 (0.10.3) 1 (12)
20152025 1.9 (1.03.6) 18 (943) 1.9 (1.03.8) 18 (842) 1.4 (0.82.6) 12 (726)
20252035 2.0 (1.14.0) 18 (943) 2.0 (1.14.1) 16 (839) 2.4 (1.34.6) 20 (10–48)
West 20052015 0.2 (0.10.5) 4 (29)) 0.3 (0.10.6) 4 (29) 0.0 (0.00.1) 0 (01)
20152025 0.5 (0.21.1) 6 (315) 0.5 (0.21.2) 6 (316) 0.3 (0.20.7) 4 (210)
20252035 0.6 (0.31.3) 6 (315) 0.6 (0.31.5) 6 (315) 0.6 (0.31.4) 7 (316)
South Africa 20052015 0.5 (0.31.0) 11 (622) 0.6 (0.31.0) 11 (623) 0.1 (0.00.1) 1 (12)
20152025 0.9 (0.51.8) 20 (148) 1.0 (0.51.9) 19 (946) 0.7 (0.41.3) 13 (727)
20252035 1.0 (0.52.0) 19 (948) 1.0 (0.52.0) 17 (843) 1.2 (0.62.3) 22 (153)
Data are as defined for the countries and regions given in Table 1. Data are given separately for each region and for South Africa over the next ten, twenty, and thirty years. Full coverage
of MC is reached in 2015. The table gives the reduction in incidence and deaths, over each ten-year period, and in prevalent cases at the end of each ten-year period. Reductions are
relative to the baseline which assumes no change in MC prevalence. The calculations are done using the expected reduction in female-to-male transmission from the RCT and using the
lower and upper 95% confidence limits of the reduction observed in the RCT [9].
DOI: 10.1371/journal.pmed.0030262.t002
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Supporting Information
Figure S1. The Increase of MC in South Africa Starting from a
Coverage of 35% and Reaching Full Coverage in 2015 (Red Line) and
2010 (Blue Line)
Found at DOI: 10.1371/journal.pmed.0030262.sg001 (365 KB JPG).
Figure S2. The Percentage of All HIV Cases That Occur in Women, as
a Function of Circumcision Parameters
(A) Circumcision is assumed to have no protective beneﬁt for women
(pf ¼ 0).
(B) Circumcision coverage is 100% (v ¼ 1). Other parameters were
chosen with reference to the South African HIV epidemic as
discussed in the main text: d¼0.102 yr1, c/m¼0.52 y1, c/f¼1.04 y1.
Found at DOI: 10.1371/journal.pmed.0030262.sg002 (2.7 MB JPG).
Figure S3. Ratio of the Prevalence of HIV in Circumcised to
Uncircumcised Men at the Steady State Assuming an Average
Infectious Period of 9.8 Years
The relationship is almost completely independent of the circum-
cision coverage, v, and the possible protective effect for women, pf.
Other parameters: v ¼ 1, pf ¼ 0, c/m¼ 0.52/y, and c/f ¼ 1.04/y.
Found at DOI: 10.1371/journal.pmed.0030262.sg003 (490 KB JPG).
Figure S4. Comparison of Three-Group (Blue Line) and the
Equivalent One-Group (Red Line) Models
Parameter values: v¼0.35, pm¼0.60, pf¼0, c/m¼0.52/y, and c/f¼1.04/
y, d ¼ 0.102/y, and p ¼ 0.29.
Found at DOI: 10.1371/journal.pmed.0030262.sg004 (7.8 MB TIF).
Figure S5. Absolute Difference between the Percent Prevalence as
Predicted by the One-Group (Collapsed) Model and the Three-Group
Model for Different Levels of MC Coverage
The lines give different levels of protective efﬁcacy pm: green, 0.76;
red, 0.60; black, 0.32. Other parameters are the same as in Figure S4.
Found at DOI: 10.1371/journal.pmed.0030262.sg005 (431 KB JPG).
Figure S6. Force of Infection, Scaled to One at Zero Prevalence, as a
Function of Prevalence
The red line is estimated from survey data for Carletonville, South
Africa. The green line assumes that the risk declines exponentially
with prevalence, the blue line that the risk has the same value for all
those who are at risk as assumed in the EPP model. The curves are
scaled to pass through the point where the curve based on the
Carletonville data passes through the prevalence among men in the
survey (21%).
Found at DOI: 10.1371/journal.pmed.0030262.sg006 (587 KB JPG).
Protocol S1. MC and HIV in Africa
Found at DOI: 10.1371/journal.pmed.0030262.sd001 (5.1 MB DOC).
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Editors’ Summary
Background. Africa is the continent most affected by HIV/AIDS, and it is
important to consider all possible means of reducing the spread of HIV
infection. Male circumcision has been a tradition in many parts of Africa
for hundreds of years. Boys who are circumcised usually have it done in
late childhood or their early teenage years. It was noticed some years
ago that those African groups in which circumcision is routinely done on
all boys have fewer cases of HIV/AIDS than are found in groups where
circumcision is not a tradition. This finding gave rise to the idea that
circumcision might give a degree of protection against HIV, though it
was recognised that some other, unknown difference between these
groups of people might actually be the important factor. In 2005 a trial
was reported from the Orange Farm area of South Africa, in which
uncircumcised men were offered the chance to be circumcised. The men
who agreed were divided at random into those who had the operation
straightaway and those who were to have it two years later. During the
next 18 months, the number of new cases of HIV infection was much
higher amongst the men who had not been circumcised. Circumcision
did therefore seem to offer a measure of protection against infection.
This protective effect was estimated at being about 60%. Similar trials are
under way in other parts of Africa but there are no results available from
them at this stage.
Why Was This Study Done? If the level of effectiveness of circumcision
suggested by the South African trial is correct, then, as one part of a
range of measures to reduce the spread of HIV, it would seem logical to
encourage the practice of male circumcision. It would be useful to have
an estimate of just how many new cases could be prevented and how
many lives would be saved by the promotion of male circumcision.
Calculations would have to allow for various factors, such as the present
level of HIV infection, which varies from one country to another, and the
fact that many men are already circumcised.
What Did the Researchers Do and Find? This research did not involve
collecting any new data. The researchers used mathematical modelling
to make calculations. They based their model on data from the Orange
Farm trial and on information from various sub-Saharan African countries
on the proportion of men who are circumcised and the proportion
who are HIV-positive. They made the assumption that if circumcision is
intensively promoted, all men in those countries will be circumcised in 10
years time. They calculated the number of new cases that would be
prevented and the lives that would be saved in ten years, 20 years, and
30 years time. Their best estimate is that with the promotion of male
circumcision, two million cases and 0.3 million deaths will be avoided in
ten years time. Over the following ten years, according to the researchers’
model, a further 3.7 million cases and 2.7 million deaths would be
prevented. Most of the initial impact would be in men, but the reduction
in the number of HIV-positive men would in time also lower the risk of
women becoming infected. Overall, on the basis of these calculations,
male circumcision would reduce the rate of infections by about 37%—
both female-to-male and male-to-female transmission. The size of the
impact would vary from one country to another; it would be greatest in
southern Africa where HIV infection rates are high and circumcision rates
relatively low compared with the rest of sub-Saharan Africa.
What Do These Findings Mean? Male circumcision alone cannot bring
the HIV/AIDS epidemic in Africa under control. Even circumcised men can
become infected, though their risk of doing so is much lower. However,
the researchers call for the promotion of male circumcision to become a
major part of AIDS control programmes. Their results are based on the
findings of just one study (the Orange Farm trial), and it will be important
to repeat the calculations when further studies have been completed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030262:
 The Orange Farm trial was published in PLoS Medicine. Several articles
discussing the trial were also published in the same issue of the journal
 The Joint United Nations Programme on HIV/AIDS (UNAIDS) has
information about the state of the HIV/AIDS epidemic and prevention
strategies worldwide. It produces an annual report and has documents
on a wide range of topics
 AEGIS is the world’s largest searchable database on HIV and AIDS.
 Many organizations provide information on AIDS prevention—for
example, the Terrence Higgins Trust
 The World Bank’s Global HIV/AIDS Program has a report about male
circumcision and HIV infection
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